title: Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.
authors.affiliation: Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier, Switzerland maapro@genolier.net.
authors.forename: M
authors.initials: M
authors.lastname: Aapro
authors.affiliation: Department of Gynecology and Obstetrics, Höchst Frankfurt Clinic, Academic Hospital of the Goethe University, Frankfurt.
authors.forename: V
authors.initials: V
authors.lastname: Moebus
authors.affiliation: Geriatric Breast Center, Evangelina Bethesda Hospital for Breast Diseases, Nordrhein-Westfalen, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Nitz
authors.affiliation: Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, USA.
authors.forename: J
authors.initials: J
authors.lastname: O'Shaughnessy
authors.affiliation: Department of Medical Oncology, IRCCS University Hospital San Martino-IST, National Institute for Cancer Research, Genova, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.affiliation: Department of Obstetrics and Gynecology, Helios Clinic Berlin-Buch, Berlin, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Untch
authors.affiliation: Amgen, Inc., Thousand Oaks.
authors.forename: D
authors.initials: D
authors.lastname: Tomita
authors.affiliation: Amgen, Inc., Thousand Oaks.
authors.forename: C
authors.initials: C
authors.lastname: Bohac
authors.affiliation: Edith Sanford Breast Cancer Research, Sioux Falls, USA.
authors.forename: B
authors.initials: B
authors.lastname: Leyland-Jones
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans
chemical_list: D059451:Biosimilar Pharmaceuticals; D006397:Hematinics